The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Clinical Research on Alzheimer’s Disease: Progress and Perspectives
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Cited by
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Self-citationWang, H., Zhang, F.-F., Xu, Y., Fu, H.-R., Wang, X.-D., Wang, L., Chen, W., Xu, X.-Y., Gao, Y.-F., Zhang, J.-G., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa048 · Cited by 84
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
“Phase III clinical trials Mild AD Donanemab A monoclonal antibody that targets a modified form of beta-amyloid called N3pG Phase III clinical trials Early AD Tauvid Imaging (flortaucipir F18) A diagnostic imaging agent that targets tau protein Approved on May 2020 Detection of tau pathology in the brain Leqembi (Lecan…”
BackgroundInfluentialNeurotrophin receptor p75 mediates amyloid β-induced tau pathology
Shen, L.-L., Li, W.-W., Xu, Y.-L., Gao, S.-H., Xu, M.-Y., Bu, X.-L., Liu, Y.-H., Wang, J., Zhu, J., Zeng, F., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104567 · Cited by 59
Self-citationWhite matter damage in Alzheimer’s disease: contribution of oligodendrocytes
Zhou, J., Zhang, P., Zhang, B., & Kong, Y. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221021115321 · Cited by 18
“Previous studies have shown that the main pathological features of AD are extracellular senile plaques composed of aggregated β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles (NFT) containing hyperphosphorylated tau protein, Aβ cerebral amyloid angiopathy A, and neuronal loss caused by Aβ deposition on t…”
Background
Metadata
- Authors
- Sun, B.-L., Li, W.-W., Zhu, C., Jin, W.-S., Zeng, F., Liu, Y.-H., Bu, X.-L., Zhu, J., Yao, X.-Q., & Wang, Y.-J.
- Venue
- Neuroscience Bulletin
- Published
- 2018-06-28
- Volume
- 34
- Issue
- 6
- Pages
- 1111-1118
- ISSN
- 1995-8218 (ISSN-L)
- 1673-7067
- OpenAlex
- W2809922718
- Cited by
- 161
- References
- 31
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Research on Alzheimer’s Disease: Progress and Perspectives. https://app.cochat.ai/papers/10.1007/s12264-018-0249-z
- The paper
- Sun, B.-L., Li, W.-W., Zhu, C., Jin, W.-S., Zeng, F., Liu, Y.-H., Bu, X.-L., Zhu, J., Yao, X.-Q., & Wang, Y.-J. (2018). Clinical Research on Alzheimer’s Disease: Progress and Perspectives. Neuroscience Bulletin. https://doi.org/10.1007/s12264-018-0249-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.